Thiopurines, a previously unrecognised cause for fatigue in patients with inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 3, Issue 3, 2009, Pages 196-199

  Lee, Thomas W T ^a   Iser, John H ^a   Sparrow, Miles P ^a   Newnham, Evan D ^a   Headon, Belinda J ^a   Gibson, Peter R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

6 mercaptopurine; Azathioprine; Crohn's disease; Inflammatory Bowel Disease; Thiopurines; Ulcerative colitis

Indexed keywords

6 THIOGUANINE NUCLEOTIDE; AZATHIOPRINE; CORTICOSTEROID; DRUG METABOLITE; MERCAPTOPURINE; MESALAZINE; METHYLMERCAPTOPURINE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON CROHN DISEASE; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEMALE; HUMAN; LETHARGY; MALE; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 67651094016     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.03.004     Document Type: Article

References (13)

1. Jager A., Sleijfer S., and van der Rijt C.C. The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?. Eur J Cancer 44 2 (2008) 175-181
2. Inagaki M., Isono M., Okuyama T., et al. Plasma interleukin-6 and fatigue in terminally ill cancer patients. J. Pain Symptom Manage 35 2 (2008) 153-161
3. Lichtenstein G.R., Bala M., Han C., DeWoody K., and Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 8 4 (2002) 237-243
4. Minderhoud I.M., Oldenburg B., van Dam P.S., and van Berge-Henegouwen G.P. High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. Am J Gastroenterol 98 5 (2003) 1088-1093
5. Gasche C., Lomer M.C.E., Cavill I., and Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 53 8 (2004) 1190-1197
6. Bruner A.B., Joffe A., Duggan A.K., Casella J.F., and Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls.[see comment]. Lancet 348 9033 (1996) 992-996
7. Bjornsson E., Simren M., Olsson R., and Chapman R.W. Fatigue in patients with primary sclerosing cholangitis. Scand J Gastroenterol 39 10 (2004) 961-968
8. Ranjbaran Z., Keefer L., Farhadi A., Stepanski E., Sedghi S., and Keshavarzian A. Impact of sleep disturbances in inflammatory bowel disease. J Gastroenterol Hepatol 22 11 (2007) 1748-1753
9. Karhadkar A.S., Schwartz H.J., Arora M., and Dutta S.K. Severe muscular weakness: an unusual adverse effect of azathioprine therapy. J Clin Gastroenterol 40 7 (2006) 626-628
10. Hindorf U., Lindqvist M., Hildebrand H., Fagerberg U., and Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 24 2 (2006) 331-342
11. Marinaki A.M., Ansari A., Duley J.A., et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14 3 (2004) 181-187
12. Gearry R.B., Roberts R.L., Barclay M.L., and Kennedy M.A. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14 11 (2004) 779-781
13. Sparrow M.P., Hande S.A., Friedman S., et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.[see comment]. Aliment Pharmacol Ther 22 5 (2005) 441-446